Bristol-Myers Squibb’s sales lift

Bristol-Myers Squibb reported quarterly earnings that exceeded expectations yesterday, fuelled by strong sales of cancer and diabetes drugs, but stuck to its earlier full-year 2013 profit forecast. The pharma firm earned $692m (£428m) in the third quarter, it said. Global revenue rose nine per cent to $4.07bn, topping Wall Street expectations of $3.99bn. Diabetes drug Onglyza and a related drug called Kombiglyze had combined sales of $211m.